These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 31741435

  • 1. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME, Kosiborod M.
    Am J Cardiol; 2019 Dec 15; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [Abstract] [Full Text] [Related]

  • 2. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 07; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 5. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE, van den Donk M, Wiersma T.
    Ned Tijdschr Geneeskd; 2019 Jan 14; 163():. PubMed ID: 30676706
    [Abstract] [Full Text] [Related]

  • 6. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E, DeFronzo RA.
    Eur Heart J; 2015 Sep 07; 36(34):2288-96. PubMed ID: 26063450
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL, Davis TME.
    Clin Ther; 2017 May 07; 39(5):1012-1025. PubMed ID: 27863704
    [Abstract] [Full Text] [Related]

  • 8. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.
    Eur J Heart Fail; 2020 Feb 07; 22(2):196-213. PubMed ID: 31816162
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Sim R, Chong CW, Loganadan NK, Fong AYY, Navaravong L, Hussein Z, Khunti K, Lee SWH.
    Diabet Med; 2022 Mar 07; 39(3):e14780. PubMed ID: 34962662
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of glucose-lowering therapies on heart failure.
    Nassif M, Kosiborod M.
    Nat Rev Cardiol; 2018 May 07; 15(5):282-291. PubMed ID: 29368701
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS.
    Postgrad Med; 2017 Nov 07; 129(8):811-821. PubMed ID: 28749197
    [Abstract] [Full Text] [Related]

  • 19. Treatment of Diabetes in Patients with Heart Failure.
    Bowes CD, Lien LF, Butler J.
    Curr Cardiol Rep; 2018 Aug 27; 20(10):97. PubMed ID: 30151728
    [Abstract] [Full Text] [Related]

  • 20. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG, Vrijlandt PJWS.
    Ned Tijdschr Geneeskd; 2020 Oct 15; 164():. PubMed ID: 33201636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.